Aion Therapeutics Inc.

CSE: AION

Company Overview

Aion Therapeutics Inc. specializes in the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceutical compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations and other medicinal plants through its wholly owned subsidiary, AI Pharmaceuticals Jamaica Limited.

In addition, the company has a joint venture agreement with a private, vertically integrated licensed producer under the Cannabis Act to offer contract tolling extraction services to third-party businesses.

Financial Highlights

$0

Revenue (ttm)

-$1,500

Gross Profit (ttm)

-$0.06

Diluted EPS (ttm)

Management Team

Mr. Graham Simmonds
CEO, COO & Exec. Vice Chair of Board

Mr. Rakesh Malhotra B.Com., C.A., F.C.A., FCA (India), C.P.A., CPA, (U
Chief Financial Officer

Dr. Stephen D. Barnhill M.D.
Exec. Chair of the Board

Dr. Herbert A. Fritsche Jr., M.D., Ph.D.
Chief Science Officer

Dr. Anthony J. Hall F.A.C.S., FAANS, M.D.
Medical Director & Independent Director

Ms. Patricia Purdy
Corp. Sec.

Mr. Paul Burke
Pres of AI Pharmaceuticals

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$357,508

Shares Outstanding
30,705,183

Shares Short (% of Float)
()

Insider Ownership
24%